ArticleClinical ophthalmology (Auckland, N.Z.)2025
Faricimab for Refractory Neovascular Age-Related Macular Degeneration: Retrospective Real-World Evidence from India.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the anatomical and functional outcomes of faricimab in eyes with refractory neovascular age-related macular degeneration (nAMD) in a real-world Indian cohort over a six-month period. Patients and Methods: In this retrospective, multicenter study, 24 eyes with refractory nAMD were switched to faricimab on a pro-re-nata regimen between January 2024 and December 2024. Patients underwent monthly evaluation for three months, then per physician discretion, with measurement of best-corrected visual acuity (BCVA), central foveal thickness (CFT), and proportions of eyes with intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED). Results: The cohort's mean age was 68.1 (±10.6) years, and prior to switching had received an average of 11.4 (±9.1) anti-VEGF injections. During the six-month period, eyes underwent a mean of 2.63 (± 1.34) faricimab injections (range, 1-5): 25.0% received one injection, 29.2% two, 16.7% three, 16.7% four, and 12.5% five. Mean BCVA improved from 0.66 (±0.4) logMAR at baseline to 0.47 (±0.34) at month 1, 0.35 (±0.32) at month 2, and 0.27 (±0.27) at months 3 and 6 ( Conclusion: In this real-world Indian cohort of refractory nAMD, faricimab delivered robust visual gains, significant CFT reduction, and high rates of fluid resolution, with over half of eyes requiring ≤2 injections over six months, supporting its role as an effective switch therapy. Further prospective studies are warranted to optimize dosing intervals and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.